Retrospective Study
Copyright ©The Author(s) 2024.
World J Psychiatry. Dec 19, 2024; 14(12): 1876-1885
Published online Dec 19, 2024. doi: 10.5498/wjp.v14.i12.1876
Table 1 Baseline data of patients with non-small cell lung cancer
Projects
n
TG (n = 57)
CG (n = 35)
χ2/t
P value
Sex, n (%)0.0090.925
    Male6138 (66.67)23 (65.71)
    Female3119 (33.33)12 (34.29)
Age, mean ± SD59.77 ± 5.2260.74 ± 6.18-0.8070.422
BMI (kg/m2), mean ± SD21.44 ± 1.8421.20 ± 2.000.5840.561
Hypertension history, n (%)0.0010.973
    Find138 (14.04)5 (14.29)
    Nil7949 (85.96)30 (85.71)
History of diabetes, n (%)0.0740.785
    Find74 (7.02)3 (8.57)
    Nil8553 (92.98)32 (91.43)
Duration of disease (month), mean ± SD8.82 ± 6.049.00 ± 2.20-0.3890.698
Pathological stage, n (%)0.0380.981
    IIIb2616 (28.07)10 (28.57)
    IIIc5232 (56.14)20 (57.14)
    IV149 (15.79)5 (14.29)
Pathological classification, n (%)0.0250.988
Adenocarcinoma4327 (47.37)16 (45.71)
Squamous carcinoma3622 (38.60)14 (40.00)
Others138 (14.04)5 (14.29)
Tumor diameter (cm), mean ± SD3.14 ± 1.163.17 ± 1.13-0.1220.903
Table 2 Karnofsky performance status scores
GroupnKPS scores
Before treatment
After treatment
TG5750 (40, 60)60 (40, 70)
CG3550 (40, 60)50 (40, 60)
χ20.01512.394
P value0.9920.006
Table 3 Therapeutic efficacy in the treatment group and control group, n (%)
Group
n
CR
PR
SD
PD
DCR
χ2
P value
TG5713 (22.81)15 (26.32)13 (22.81)16 (28.06)41 (71.94)3.9620.047
CG353 (8.57)5 (14.29)10 (28.57)17 (48.57)18 (51.43)
Table 4 Occurrence rate of adverse reactions in the treatment group and control group, n (%)
Group
n
Breathing difficulties
Diarrhea
Vomiting
Proteinuria
Overall response rate
χ2
P value
TG571 (1.75)2 (3.51)2 (3.51)1 (1.75)6 (10.52)0.0180.893
CG351 (2.86)1 (2.86)1 (2.86)1 (2.86)4 (11.44)